Assessing Zoetis (ZTS) Valuation As Earnings Expectations Build Ahead Of February 12 Results

Simply Wall St.02-10 11:20

AdvertisementDividend affirmation and earnings catalyst Zoetis (ZTS) has reaffirmed its shareholder return plans with a second quarter 2026 dividend of $0.53 per share, while investors watch the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610697935?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/215548781-main-header/1756213611450","is_english":true,"pubTime":"2026-02-10 11:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610697935","market":"us","top_or_hot":-1,"title":"Assessing Zoetis (ZTS) Valuation As Earnings Expectations Build Ahead Of February 12 Results","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementDividend affirmation and earnings catalyst Zoetis (ZTS) has reaffirmed its shareholder return plans with a second quarter 2026 dividend of $0.53 per share, while investors watch the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/news/assessing-zoetis-zts-valuation-as-earnings-expectations-buil\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Zoetis (ZTS) Valuation As Earnings Expectations Build Ahead Of February 12 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Zoetis (ZTS) Valuation As Earnings Expectations Build Ahead Of February 12 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-10 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/news/assessing-zoetis-zts-valuation-as-earnings-expectations-buil><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementDividend affirmation and earnings catalyst Zoetis (ZTS) has reaffirmed its shareholder return plans with a second quarter 2026 dividend of $0.53 per share, while investors watch the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/news/assessing-zoetis-zts-valuation-as-earnings-expectations-buil\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZTS","symbol_name":"Zoetis Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/news/assessing-zoetis-zts-valuation-as-earnings-expectations-buil","article_id":"2610697935","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/215548781-main-header/1756213611450"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/news/assessing-zoetis-zts-valuation-as-earnings-expectations-buil","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610697935","pubTimestamp":1770693608,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Dividend affirmation and earnings catalyst\nZoetis (ZTS) has reaffirmed its shareholder return plans with a second quarter 2026 dividend of $0.53 per share, while investors watch the upcoming February 12 earnings and guidance for signals on future performance.\nSee our latest analysis for Zoetis.\nZoetis shares trade at $127.30, with a 90 day share price return of 5.98% contrasting with a 1 year total shareholder return decline of 24.87%. This suggests recent momentum has not yet translated into...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ZTS":"Zoetis Inc.","BGSX":"Build Acquisition Corp"},"translate_title":"随着2月12日业绩公布前盈利预期的增强，评估硕腾(ZTS)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZTS":1.5,"BGSX":1.5},"content_text":"AdvertisementDividend affirmation and earnings catalyst Zoetis (ZTS) has reaffirmed its shareholder return plans with a second quarter 2026 dividend of $0.53 per share, while investors watch the upcoming February 12 earnings and guidance for signals on future performance. See our latest analysis for Zoetis. Zoetis shares trade at $127.30, with a 90 day share price return of 5.98% contrasting with a 1 year total shareholder return decline of 24.87%. This suggests recent momentum has not yet translated into longer term recovery. If this dividend update has you reassessing your portfolio, it could be a good moment to scan the broader market using our screener of 26 healthcare AI stocks as potential new ideas to research. With Zoetis trading at $127.30, an indicated intrinsic discount and a pullback in 1 year and multi year returns, investors now face a key question: is this weakness an opening, or is the market already pricing in future growth? Most Popular Narrative: 20% Undervalued With Zoetis at $127.30 against a narrative fair value of about $158, the gap between price and projected cash flows is drawing attention ahead of earnings.  Ongoing innovation and accelerated R&D output, with expectations for a major new product approval in a key market every year over the next few years, positions Zoetis to expand addressable markets, launch higher-margin products, and protect market share, positively impacting organic revenue growth and net margins.  Read the complete narrative. Want to see what is baked into that valuation gap? This narrative leans on steady revenue gains, firm margins, and a richer earnings multiple than today. The full breakdown shows how those pieces fit together. Result: Fair Value of $158.22 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that upside case runs into real friction if OA pain products keep stumbling or if rivals in dermatology and parasiticides begin to chip away at key franchises. Find out about the key risks to this Zoetis narrative.  Build Your Own Zoetis Narrative If you see the story differently or prefer to test the inputs yourself, you can build a custom Zoetis view in minutes. To begin, start with Do it your way. A great starting point for your Zoetis research is our analysis highlighting 6 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? If you stop your research with just one stock, you risk missing out on other opportunities that might fit your goals even better right now.  Spot potential value opportunities early by scanning our list of screener containing 24 high quality undiscovered gems that meet strict fundamental checks before they hit the mainstream radar. Prioritize resilience by reviewing 83 resilient stocks with low risk scores that score well on our risk metrics while still offering room for growth. Strengthen your income focus by checking 14 dividend fortresses that pair higher yields with business models built around consistent payouts.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Zoetis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610697935","isCrawlerRequest":true}